Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7934 results

Sort By:

A Study of EBC-129 in Advanced Solid Tumours

Study ID: NCT05701527
Start Date: 2023-04-28
End Date: 2026-12-24
Study Type

Interventional

Study Phase

Phase1

No. of Participants

84

Intervention / Treatment

EBC-129

Pembrolizumab

Sponsor

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Source: clinicaltrials.gov

Share:
Add to list

Effect of Ketamine on Intraoperative Motor Evoked Potentials

Study ID: NCT06140927
Start Date: 2023-12-01
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

20

Intervention / Treatment

Ketamine

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list

A Registry for People With Lung Cancer

Study ID: NCT06424327
Start Date: 2024-05-15
End Date: 2029-05-15
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

600

Intervention / Treatment

Patient-Reported Outcomes Measurement Information System

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Study ID: NCT06774027
Start Date: 2025-04-30
End Date: 2030-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Specimen collection

Non-Investigational Antibody-Drug Conjugates (ADC)

Medical Record Review

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list

Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults with Neurofibromatosis Type 1

Study ID: NCT04941027
Start Date: 2021-05-07
End Date: 2025-09-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1000

Intervention / Treatment
Sponsor

Stanford University

Source: clinicaltrials.gov

Share:
Add to list

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors

Study ID: NCT05039073
Start Date: 2022-05-02
End Date: 2027-11-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

46

Intervention / Treatment

Bentuximab Vidotin

Hematopoietic Cell Transplantation

Nivolumab

Quality-of-Life Assessment

Administration questionnaire

Sponsor

Emory University

Source: clinicaltrials.gov

Share:
Add to list

Pediatric Oncology Nutrition Intervention Trial

Study ID: NCT06175273
Start Date: 2024-01-31
End Date: 2026-03-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

45

Intervention / Treatment

Oral Nutrition Supplement

Tube Feed

Cyproheptadine

Olanzapine

Standard of Care

Sponsor

Corey Hawes

Source: clinicaltrials.gov

Share:
Add to list

Survivorship Post-HCT Optimization Program

Study ID: NCT05238376
Start Date: 2022-12-02
End Date: 2025-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

70

Intervention / Treatment

Exercise training

Sponsor

Duke University

Source: clinicaltrials.gov

Share:
Add to list

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Study ID: NCT04978727
Start Date: 2022-07-01
End Date: 2030-02-28
Study Type

Interventional

Study Phase

Phase1

No. of Participants

35

Intervention / Treatment

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years

SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years

Sponsor

Pediatric Brain Tumor Consortium

Source: clinicaltrials.gov

Share:
Add to list

Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow

Study ID: NCT03363373
Start Date: 2018-04-03
End Date: 2028-04
Study Type

Interventional

Study Phase

Phase2

No. of Participants

122

Intervention / Treatment

GM-CSF + Naxitamab

Sponsor

Y-mAbs Therapeutics

Source: clinicaltrials.gov

Share:
Add to list